The abstract is read at the publisher; the summary is JClub's.
Emerging immune-related biomarkers are linked to histology-independent prediction of immunotherapy response in lung cancer, addressing inconsistent performance of PD-L1, tumor mutational burden, and microsatellite instability.
- Why it matters: Current biomarkers show inconsistent predictive value across lung cancer histologies, while tumor heterogeneity and therapy-driven changes in the tumor microenvironment complicate reliable biomarker development.
- What they did: This review summarizes limitations of established markers and highlights emerging immune-related measures of innate infiltration, antigen presentation capacity, cytotoxic T-cell activation, and inflammatory signaling as functional TME indicators.
- The result: Integrated immune signatures that capture patient profiles most likely to respond to immune checkpoint inhibitors and next-generation immunotherapies require robust prospective validation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.